Compass reports Phase 3 psilocybin COMP360 results as “promising yet modest,” plus US legislative updates and Helus DMT depression data

Psilocybin and DMT therapy updates headline the newsletter, with Compass reporting results from its second Phase 3 trial of COMP360 (synthetic psilocybin) for treatment-resistant depression. Compass says two 25 mg doses produced a statistically significant, clinically meaningful reduction versus 1 mg placebo, using MADRS score changes and a reported response threshold based on a 25% decrease. The newsletter also highlights criticism from researchers about how “clinically meaningful” and “response” definitions may have shifted compared with earlier work. The issue also covers US policy momentum: Missouri hearings consider ibogaine research and a supervised psilocybin pathway for certain conditions, while New Hampshire advances a state-run medical psilocybin program. A related research note summarizes a Nature Medicine Phase 2a study suggesting Helus’s IV DMT formulation may reduce depression symptoms, with implications for an intramuscular DMT program.